Nasal oxytocin for social deficits in childhood autism: a randomized controlled trial.
Oxytocin spray gives no extra social boost to autistic youths already receiving parent-mediated social-skills training.
01Research in Context
What this study did
Researchers gave boys with autism either oxytocin nose spray or fake spray. All families also did parent-child social skills training.
The team wanted to know if the hormone would boost emotion recognition and social interaction more than training alone.
What they found
After the sessions, the oxytocin group looked the same as the placebo group. No gains in reading faces, talking with peers, or daily behavior.
The drug added zero extra benefit to the behavioral training.
How this fits with other research
EGranieri et al. (2020) pooled 18 social-skills trials and found medium-to-large gains for both in-person and app-based training. The 2014 oxytocin study is inside that pool; the drug still showed no boost.
Prinsen et al. (2025) gave the same spray to young adults. Again, no overall effect, but a small subset with high baseline oxytocin did improve. This extends the null youth finding and flags a possible biomarker.
Marino et al. (2020) and Ibrahim et al. (2021) both ran social-cognitive groups without drugs. Kids who worked with robots or got neural feedback made real social gains. These positive results sit opposite the oxytocin null, underscoring that behavioral methods still carry the weight of evidence.
Why it matters
BCBAs can skip the hormone and keep using proven behavioral packages. Focus your hours on structured social-skills groups, peer modeling, or robot-assisted modules that already show measurable gains. If a family asks about oxytocin, share that the strongest data so far say it does not help beyond good teaching.
Want CEUs on This Topic?
The ABA Clubhouse has 60+ free CEUs — live every Wednesday. Ethics, supervision & clinical topics.
Join Free →Keep running your regular SST lesson; leave the nose spray out of the plan.
02At a glance
03Original abstract
The last two decades have witnessed a surge in research investigating the application of oxytocin as a method of enhancing social behaviour in humans. Preliminary evidence suggests oxytocin may have potential as an intervention for autism. We evaluated a 5-day 'live-in' intervention using a double-blind randomized control trial. 38 male youths (7-16 years old) with autism spectrum disorders were administered 24 or 12 international units (depending on weight) intranasal placebo or oxytocin once daily over four consecutive days. The oxytocin or placebo was administered during parent-child interaction training sessions. Parent and child behaviours were assessed using parent reports, clinician ratings, and independent observations, at multiple time points to measure side-effects; social interaction skills; repetitive behaviours; emotion recognition and diagnostic status. Compared to placebo, intranasal oxytocin did not significantly improve emotion recognition, social interaction skills, or general behavioral adjustment in male youths with autism spectrum disorders. The results show that the benefits of nasal oxytocin for young individuals with autism spectrum disorders may be more circumscribed than suggested by previous studies, and suggest caution in recommending it as an intervention that is broadly effective.
Journal of autism and developmental disorders, 2014 · doi:10.1007/s10803-013-1899-3